Pre-Conference Workshops - Oct 21 - JT (Japan Time, GMT+09:00)
Pre-Conference Workshops - Oct 21 - JT (Japan Time, GMT+09:00)
Add-on this option pre-conference workshop to your main conference registration package and gain a comprehensive overview of antibody engineering in an easy-to-follow classroom setting to help you prepare for the main conference program.
- Workshop registration begins at 7:30 am
- Morning Break: ~10:30-10:50
WORKSHOP OVERVIEW
Today’s wealth of knowledge of protein structures will be reviewed along with the genetics of diversity generation of antibodies, to give insights into the best strategies for improving protein function. There is particular emphasis on the choice of a functional assay to effectively monitor the changes in a desired property, and the use of functional enrichment steps where a library approach is employed. Not only is amino acid sequence amenable to engineering, but glycan structures and other modifications may also be engineered. The course will focus on the engineering and enhancement of antibodies and antibody-like scaffolds. Examples will include work on antibody fragment affinity improvement by 100-fold to low pM affinity. Also, the engineering of bispecific antibodies by diverse approaches and the adaptation to generate Chimeric Antibody Receptor (CAR) constructs will be discussed. Expression platforms for producing antibodies for testing and for manufacture will also be covered. A background in biochemistry and molecular biology is useful, as the course is designed to progress rapidly from simple to advanced concepts.
INSTRUCTOR
David Bramhill, Ph.D., Founder, Bramhill Biological Consulting, LLC and Research Corporation Technologies
COURSE AGENDA
- Functions amenable to engineering: affinity, specificity, stability, solubility, immunogenicity
- The measure of success: functional assays
- Engineering by design
- Engineering by random mutation
- Designed libraries
- Display technologies
- Improving manufacturing by protein engineering methods
- Glycosylation engineering – function and homogeneity
- Other protein modifications
- Immunogenicity engineering
- Bispecific antibodies
- Antibody-drug conjugates (ADCs)
- CAR-T strategies
- Expression of antibodies and fragments for discovery and testing
- Manufacturing platforms for antibodies and fragments
- David Bramhill, PhD - Consultant, Bramhill Biological Consulting, LLC
Add-on this option pre-conference workshop to your main conference registration package and gain a comprehensive overview of bioconjugate and ADC design and development in an easy-to-follow classroom setting to help you prepare for the main conference program.
- Workshop registration begins at 12:30 pm
- Afternoon Break: ~ 3:30-3:50
WORKSHOP OVERVIEW
This workshop covers the key aspects of bioconjugate/ADC design, why each piece is important and how each can synergise to make an optimized product. It will give a comprehensive overview of the current state-of-the-art approaches available for ADCs, nanoparticles and conjugate vaccines, and provides an introductory framework so participants can rapidly identify issues and solutions in their specific bioconjugate projects. It is aimed to provide even beginners with explanations of the nomenclature and science. The teams involved in bioconjugate development need both chemists and biologists to work together effectively. The course provides opportunity to better understand both aspects of the science and thus enhance communication within your team.
INSTRUCTOR
David Bramhill, Ph.D., Founder, Bramhill Biological Consulting, LLC and Research Corporation Technologies
WORKSHOP TOPICS TO BE DISCUSSED
- Antibody and Protein Structure
- ADCs
- Nanoparticle designs
- Payload decisions
- Conjugate vaccine components: antigens, adjuvants, etc.,
- Bioconjugation by chemistry and enzyme
- Linker designs for release or stability
- Linkers and solubility
WHAT WILL YOU LEARN?
- Gain an overview of the key aspects and design parameters for diverse bioconjugates.
- Scientific terms and acronyms relating to ADCs and bioconjugates will be defined and explained.
- Current state-of-the-art solutions for the various challenges faced in developing an ADC or bioconjugate.
- Specific challenges for particular product formats – vaccines, ADCs, nanoparticles, etc.
- Better understand what the others in your bioconjugate team are working to accomplish.
WHO SHOULD ATTEND?
Scientists and managers involved in the development of therapeutic bioconjugates – ADCs, nanoparticles, conjugate vaccines – in pharma and biotech companies.
- David Bramhill, PhD - Consultant, Bramhill Biological Consulting, LLC